Michael Hubalek
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial
Fitzal F, Gnant M, Greil R, Soelkner L, Schrenk P, Bartsch R, Singer C, Balic M, Hubalek M, Steger G, Knauer M, Bjelic-Radisic V, ABCSG. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg 2018
Apr 24, 2018Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial
Apr 24, 2018Ann Surg 2018
Fitzal Florian, Gnant Michael, Greil Richard, Soelkner Lidija, Schrenk Peter, Bartsch Rupert, Singer Christian, Balic Marija, Hubalek Michael, Steger Günther, Knauer Michael, Bjelic-Radisic Vesna, ABCSG
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer
Filipits M, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens J, Gnant M, Dubsky P, Mlineritsch B, Singer C, Nielsen T, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Austrian Breast and Colorectal Cancer Study Group. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 2014; 20:1298-305.
Feb 11, 2014The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer
Feb 11, 2014Clin Cancer Res 2014; 20:1298-305
Filipits Martin, Bauernhofer Thomas, Hubalek Michael, Knauer Michael, Trapl Harald, Fesl Christian, Schaper Carl, Ferree Sean, Liu Shuzhen, Cowens J Wayne, Gnant Michael, Dubsky Peter, Mlineritsch Brigitte, Singer Christian F, Nielsen Torsten O, Rudas Margaretha, Greil Richard, Stöger Herbert, Jakesz Raimund, Bago-Horvath Zsuzsanna, Dietze Otto, Regitnig Peter, Gruber-Rossipal Christine, Müller-Holzner Elisabeth, Austrian Breast and Colorectal Cancer Study Group
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Lück H, Schuster T, Wollschläger K, Untch M, Thomssen C, Eidtmann H, Stickeler E, Richter B, Hubalek M, Jackisch C, Stähler A, Beckmann M, Heilmann V, Huober J, Schrader I, Loibl S, du Bois A, von Minckwitz G. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 2013; 139:779-87.
Jun 15, 2013Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Jun 15, 2013Breast Cancer Res Treat 2013; 139:779-87
Lück Hans-Joachim, Schuster Tibor, Wollschläger Kerstin, Untch Michael, Thomssen Christoph, Eidtmann Holger, Stickeler Elmar, Richter Barbara, Hubalek Michael, Jackisch Christian, Stähler Ann, Beckmann Matthias, Heilmann Volker, Huober Jens, Schrader Iris, Loibl Sibylle, du Bois Andreas, von Minckwitz Gunter